Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28

Peptide manufacturing vertical on track to begin generating revenue in August 2026; VectorMist™ 510(k) submission advancing toward FDA filing MEQUON, Wis., July 24, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced the filing...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.